TSX:AEZS - Post Discussion
Post by
prophetoffactz on Jun 17, 2024 10:38pm
Perplexity Ai on what we can expect...
Based on the information provided, we can expect the following regarding the scientific publication in the journal Biomaterials: A comprehensive scientific article was recently submitted to the Biomaterials journal detailing the results of the CHRP collaboration with McMaster University on evaluating PGX-processed YBG (PGX-YBG) for interstitial lung diseases. The key findings are: - The results were encouraging, prompting presentations at international scientific conferences.
- PGX-YBG was found to be suitable for inhalation.
- A newly discovered mechanism of action was identified, where PGX-YBG can specifically bind to macrophages (white blood cells involved in inflammation and fibrotic processes).
The submission of this comprehensive article to the prestigious Biomaterials journal suggests that the research findings are significant and novel in the field of biomaterials science, particularly for potential applications in treating interstitial lung diseases. The journal's high impact factor (14 as per the source) indicates its reputation and selectivity in publishing impactful research.
Be the first to comment on this post